The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.
 
Janet E. Murphy
Consulting or Advisory Role - Blueprint Genetics
 
Jennifer Yon-Li Wo
No Relationships to Disclose
 
David P. Ryan
Stock and Other Ownership Interests - MPM Capital
Honoraria - Research to Practice; UpToDate
Consulting or Advisory Role - MPM Capital
Patents, Royalties, Other Intellectual Property - Johns Hopkins University Press; McGraw Hill Chapter Royalties
 
Wenqing Jiang
No Relationships to Disclose
 
Beow Y Yeap
No Relationships to Disclose
 
Gabriel Dan Duda
Consulting or Advisory Role - Hexal
Research Funding - HealthCare Pharmaceuticals (Inst); Merrimack (Inst)
 
Jill N. Allen
No Relationships to Disclose
 
Lawrence Scott Blaszkowsky
Stock and Other Ownership Interests - Pfizer (I)
 
Cristina Ferrone
No Relationships to Disclose
 
Aparna Raj Parikh
Employment - Genentech
 
Ryan David Nipp
No Relationships to Disclose
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Lilly; Merck; Novartis; Sanofi
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Lipika Goyal
No Relationships to Disclose
 
Keith D Lillemoe
No Relationships to Disclose
 
Thomas F. DeLaney
Honoraria - Oakstone Publishing; UpToDate; Wolters Kluwer
 
Rakesh K. Jain
Leadership - Tekla Capital Management; Tekla Capital Management; Tekla Capital Management; Tekla Life Sciences; XTuit Pharmaceuticals
Stock and Other Ownership Interests - Enlight Biosciences; ophthotech; SynDevRx; XTuit Pharmaceuticals
Consulting or Advisory Role - Merck; Ophthotech; pfizer; Sun Pharma; SynDevRx
 
Jeffrey W. Clark
Consulting or Advisory Role - Emas pharma
Research Funding - Pfizer (Inst)
 
Yves Boucher
Consulting or Advisory Role - XTuit Pharmaceuticals
 
Carlos Fernandez-del Castillo
No Relationships to Disclose
 
Theodore S. Hong
Consulting or Advisory Role - Clinical Genomics
Research Funding - Novartis (Inst); Taiho Pharmaceutical